MOTS-c

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-C) is a 16-amino-acid peptide encoded by the mitochondrial genome. It is categorized as a mitochondria-derived peptide (MDP) that functions as a signaling molecule to regulate metabolism and promote cell stress adaptation, often linked to exercise and metabolic health.

Key Beneifts

• May support cellular energy production and metabolic function
• Commonly researched for improving exercise endurance and physical performance
• May help support healthy fat metabolism and weight management
• Research suggests potential benefits for insulin sensitivity, recovery, and healthy aging support

FDA-Approved Uses

MOTS-c has no FDA-approved use. It remains an investigational/research compound.

Regulatory Status (as of May 2026):

• Previously: FDA Category 2 (503A bulk drug substances list), compounding prohibited due to significant safety concerns (immunogenicity, peptide-related impurities, no human exposure data)
• April 15, 2026: HHS Secretary directed FDA to remove MOTS-c from Category 2 (along with 11 other peptides). Effective April 22, 2026.
• MOTS-c is no longer classified as raising ‘significant safety concerns’ by FDA.
• Next step: PCAC (Pharmacy Compounding Advisory Committee) review scheduled July 23–24, 2026 at FDA White Oak Campus. PCAC will evaluate evidence and determine whether MOTS-c should be added to Category 1, which would allow licensed 503A compounding pharmacies to prepare it with a physician’s prescription.
• 503B outsourcing facilities: Status pending PCAC review outcome.

Conditions under preclinical/early research investigation (NOT approved):

• Metabolic syndrome / Obesity / Insulin resistance
• Animal studies show prevention of diet-induced obesity and improved insulin sensitivity
• Type 2 Diabetes
• Improves glucose homeostasis and insulin sensitivity in animal models
• Age-related metabolic decline / Longevity:
• Levels decline with aging; exogenous MOTS-c improves physical capacity in aging mice
• Exercise performance and muscle homeostasis:
• Identified as an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline
• Non-alcoholic fatty liver disease (NAFLD/MASH):
• MOTS-c analog CB4211 (25 mg/day SC) studied in Phase 1b trial in patients with obesity and fatty liver

WADA Status: Prohibited at all times under S4.4, Metabolic Modulators (AMPK activators)
Athletes cannot obtain a Therapeutic Use Exemption (TUE), no approved therapeutic use exists.

Trade Names in the USA and Manufacturers

No FDA-approved trade name or manufacturer in the USA.

Original discovery:

• First identified in 2015 by Dr. Changhan (David) Lee at the University of Southern California (USC)
• Encoded by mitochondrial DNA, unique among peptides (most peptides are encoded by nuclear DNA)

Current US availability:

• As of May 2026: Grey-market research peptide vendors (‘research use only’)
• Licensed 503A compounding pharmacies: Currently NOT legal (PCAC review pending July 2026 – may change)
• No commercial pharmaceutical manufacturer or brand exists

MOTS-c Analog CB4211:

• Developer: CohBar Inc. (Menlo Park, CA)
• CB4211 is a synthetic, modified analogue of MOTS-c developed for therapeutic use
• Completed Phase 1b trial in patients with obesity and NAFLD (25 mg/day SC, 4 weeks)
• No further clinical development publicly announced as of May 2026

Stability note: MOTS-c is highly susceptible to degradation. It requires strict cold-chain storage (lyophilized powder stored at -20°C or below; reconstituted solution used immediately or within 24–48 hours refrigerated). Products from vendors with inadequate cold-chain handling may be degraded and ineffective.

Dosage

Research/off-label reported protocols (subcutaneous injection):

• Standard reported dose: 5–10 mg per injection
• Frequency: 2–3 times per week
• Cycle length: 4–8 weeks on, followed by break
• Route: Subcutaneous injection only

CB4211 analog (Phase 1b clinical trial dose):
25 mg/day subcutaneously for 4 weeks
[This is a modified analogue, not identical to MOTS-c]

Reconstitution:

• Lyophilized powder; reconstitute with Bacteriostatic Water for Injection
• Store lyophilized powder at -20°C or below
• Once reconstituted, use within 24–48 hours (refrigerated), highly unstable in solution

Critical stability issue: MOTS-c degrades rapidly in solution. This is a known challenge distinguishing it from more stable peptides. Cold-chain integrity from vendor to administration is critical. Inadequate storage likely renders the peptide inactive.

Pricing

No commercial (FDA-approved) pricing exists.

Grey-market research peptide vendors (unregulated, ‘research use only’):

• Typical price: ~$40–$120 per vial (5–10 mg)
• Monthly cost at standard research protocols (2–3x/week):
• Approximately $150–$400/month depending on dose, vendor, and vial size

If PCAC review (July 2026) is favorable:
Compounded MOTS-c from licensed 503A pharmacies expected at ~$150–$350/month
(Based on comparable compounded peptide pricing from 503A facilities)

Tips

• Monitor the July 23–24, 2026 PCAC review outcome,  this will determine whether MOTS-c becomes legally available through licensed 503A compounding pharmacies. A favorable decision would significantly improve access to pharmaceutical-quality product.
• WADA S4.4 prohibition: If you are an athlete subject to anti-doping testing, MOTS-c is prohibited at all times.
• Stability is the most critical quality consideration for MOTS-c, more so than for most peptides. Insist on: cold-chain shipping (dry ice or refrigerated), Certificate of Analysis (CoA) from third-party testing, and known manufacturer identity. Refuse any product from vendors who cannot provide these.
• MOTS-c works through AMPK activation – the same pathway as metformin. If you are already taking metformin or other AMPK activators, discuss potential additive or interactive effects with your physician.
• Animal study results (dramatic obesity prevention in mice) are unlikely to translate directly to humans – the magnitude of effect in humans will almost certainly be lower.
• Contradictory cancer signals exist in the literature (see Side Effects). Anyone with a personal or family history of cancer ,especially prostate or breast cancer – should avoid MOTS-c and consult a physician.

Side Effects

⚠️ Human safety data is extremely limited. No completed human clinical trials for MOTS-c itself.

Reported by users purchasing from grey-market sources (USADA, anecdotal):

• Injection site reactions: Irritation, redness, swelling, pain at injection site
• Increased heart rate / heart palpitations
• Insomnia / sleep disturbance
• Fever (reported)
• Fatigue (especially in first 1–3 weeks; often reported to resolve)
• Gastrointestinal disturbance: Nausea, GI discomfort
• Energy fluctuations: Initial energy dips before potential improvement

CB4211 analog (Phase 1b trial – closest human safety data available):

Reported as ‘safe and well tolerated’ in double-blind, placebo-controlled single-dose and multiple ascending dose trial in adult humans
No serious adverse events published from this trial

General peptide drug class concerns (from PMC/NCBI review):

• Antidrug antibody (ADA) formation: Production of antibodies against MOTS-c is a potential risk; the FDA specifically cited immunogenicity as a concern when it was Category 2
• Off-target effects: Unknown given lack of comprehensive human pharmacology data
• Peptide-related manufacturing impurities: FDA cited this as a concern

CANCER SIGNAL – CONTRADICTORY DATA:

• Some research suggests MOTS-c may have anti-tumor properties (via AMPK activation, which can suppress cancer cell metabolism)
• Other studies (in vitro/animal) suggest MOTS-c may promote prostate cancer and breast cancer cell growth
• These contradictory signals are unresolved. Human cancer risk is unknown.
• Anyone with active malignancy or cancer history should avoid MOTS-c

Long-term safety: Completely unknown. No long-term human studies exist.

Contraindications

No formal contraindications established (no approved label; no completed human trials).

Based on known pharmacology, FDA safety statements, and clinical guidance:

Strong caution / avoid:

• Active malignancy: Contradictory cancer signals (both pro- and anti-tumor effects reported); cancer patients should avoid until human data clarifies risk
• Personal or family history of prostate cancer or breast cancer: Specific concern signals in literature
• Pregnancy and breastfeeding: No safety data; not recommended
• Children and adolescents: No safety data; not recommended

Use with caution / physician oversight required:

• Patients on metformin or other AMPK-activating medications: Same downstream pathway – additive effects possible; monitor for hypoglycemia or excessive metabolic effects
• Patients with folate metabolism disorders: MOTS-c affects the folate cycle and one-carbon metabolism; potential interaction
• Patients with insulin-dependent diabetes: AMPK activation affects glucose metabolism; monitor blood glucose carefully
• Cardiovascular conditions (arrhythmia, palpitations history): Reported heart rate increase signals warrant caution

Athletes subject to anti-doping:

• WADA S4.4 prohibited at all times – absolute contraindication for competitive athletes in tested sports
• No TUE available

Pharmacology

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a 16-amino acid peptide with the sequence MRWQEMGYIFYPRKLR. It is unique among known human peptides in that it is encoded by mitochondrial DNA (specifically the 12S rRNA gene).

It is not encoded by nuclear DNA – making it the first identified mitochondria-derived peptide (MDP) of this type. MW approximately 2,167 Daltons. First identified in 2015 by Dr. Changhan (David) Lee at the University of Southern California.

Physiological context:

• MOTS-c is naturally produced within cells by mitochondria and circulates in human plasma
• Plasma levels DECLINE significantly with age and in metabolic disease states (obesity, insulin resistance, T2DM)
• Levels INCREASE with exercise – MOTS-c has been identified as an exercise-induced hormone
• This age-related decline has led to interest in exogenous MOTS-c supplementation as a potential longevity and metabolic intervention

Stability:

• Highly susceptible to degradation in solution (particularly at room temperature)
• Requires strict cold-chain storage: lyophilized at -20°C or below
• Reconstituted solution must be used promptly (within 24–48 hours refrigerated)
• Poor stability is the primary practical challenge for therapeutic development

Administration: Subcutaneous injection only (oral use not viable – broken down by digestive enzymes)
Blood-brain barrier: Does NOT cross the BBB when administered subcutaneously

Mechanism of action

MOTS-c’s primary mechanism centers on activation of AMPK (AMP-activated protein kinase) and modulation of one-carbon metabolism:

1. AMPK Activation (primary mechanism):
MOTS-c activates AMPK – the cell’s central energy-sensing enzyme and a master regulator of metabolism.

• AMPK activation triggers:
• Increased glucose uptake by skeletal muscle cells (independent of insulin)
• Increased fatty acid oxidation (fat burning)
• Decreased hepatic glucose production
• Improved insulin sensitivity
• Stimulation of mitochondrial biogenesis (creation of new mitochondria)

This is the same downstream pathway activated by metformin and exercise.

2. One-Carbon Metabolism and Folate Cycle Modulation:
MOTS-c modulates the folate cycle within mitochondria, affecting methionine metabolism and methylation reactions – upstream of AMPK activation in some pathways.

3. Exercise-Mimetic Effects:
MOTS-c is produced by mitochondria in response to exercise. Exogenous administration in aging mice mimicked exercise-induced metabolic improvements, including:

• Restored physical capacity in aging mice
• Improved muscle homeostasis
• Delayed age-related physical decline

This has led to it being described as a potential ‘exercise mimetic.’

4. Mitochondrial Stress Response:
MOTS-c appears to function as a mitochondria-to-nucleus retrograde signal – when mitochondria are under metabolic stress, MOTS-c is produced and travels to the nucleus to regulate gene expression and coordinate a whole-cell metabolic response.

5. Insulin Sensitization:
In animal models, MOTS-c treatment directly improved insulin receptor signaling and glucose transporter (GLUT4) expression in skeletal muscle.

Key distinction from GH secretagogues:
– MOTS-c has NO effect on growth hormone, IGF-1, or cortisol – it works through entirely different (mitochondrial/AMPK) pathways.

Result Claims from Different Companies

No major pharmaceutical company has made commercial claims (no approved drug).

Academic/research findings (published peer-reviewed data):

Lee et al., Cell Metabolism (2015) – Discovery paper:

• Identified MOTS-c as a mitochondria-derived peptide that promotes metabolic homeostasis
• Demonstrated MOTS-c treatment prevented diet-induced obesity and insulin resistance in mice
• Showed MOTS-c activated AMPK and improved insulin sensitivity in skeletal muscle
• First paper to establish MOTS-c as a regulator of metabolic function

Reynolds et al., Nature Communications (2021):

• Identified MOTS-c as an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
• Demonstrated MOTS-c levels increase with exercise in humans
• Showed exogenous MOTS-c treatment in aging mice restored physical performance
• Established the concept of MOTS-c as an ‘exercise mimetic’ for age-related decline

PMC review (2023 – MOTS-c Functionally Prevents Metabolic Disorders):

• Summarized animal evidence supporting MOTS-c as potentially effective against obesity, insulin resistance, and metabolic syndrome
• Noted MOTS-c alone reduced obesity and insulin resistance in previous animal experiments
• Highlighted that MOTS-c is ‘highly effective as a peptide drug’ based on animal data while acknowledging human data is needed

CB4211 analog (CohBar Inc., Phase 1b trial – humans):

• Dose: 25 mg/day subcutaneously for 4 weeks in adults with obesity and NAFLD
• Result: Described as ‘safe and well tolerated’ in dose-escalation study
• No efficacy outcomes published from this study as of May 2026

Alzheimer’s Drug Discovery Foundation Cognitive Vitality Report (2021):

• Noted CB4211 Phase 1b data as preliminary evidence of safety
• Noted contradictory cancer signals (potential pro-tumor vs. anti-tumor effects) as unresolved concerns requiring further research before any cognitive/longevity application

CRITICAL LIMITATION:
The overwhelming majority of MOTS-c data is from animal studies (primarily mice). Human clinical trial data is limited to a single Phase 1b trial of a MOTS-c analog (CB4211), with no efficacy outcomes published. Animal study results.

These results includes dramatic obesity prevention, are unlikely to translate at the same magnitude to humans. No pharmaceutical company has made any marketing or efficacy claims for MOTS-c as a commercial product.

Disclaimer

This content about “MOTS-c” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.

Peptides Similar to MOTS-C

Humanin
FOXO4-DRI
NAD+
Epitalon
Pinealon
5-Amino-1-MQ